Sabita Sankar graduated with honors from the National University of Singapore. She obtained a Ph.D. in Molecular and Cell Biology from the Institute of Molecular and Cell Biology. She completed her postdoctoral fellowships at Yale and Duke Universities, where her primary research interest was in vascular biology focused on TGF-1 and Angiopoietin/Tie-2 signaling.
She then spent the next several years at Celgene working in their oncology discovery group and co-led the project team that developed CC-223 and CC-115, mTOR and mTOR/DNA-PK drugs, respectively. Prior to joining Ambry, Dr. Sankar worked at several diagnostic companies, in the business development team providing genomic and proteomic solutions for Pharma clients. Dr. Sankar’s expertise includes a unique skill set of both drug discovery/diagnostics perspectives.